RFM
VKTX icon

Royal Fund Management’s Viking Therapeutics VKTX Stock Holding History

Royal Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$63.3K – 364
2024
Q3 		$63.3K Sell
1,000
-300
-23% -$17.6K ﹤0.01% 329
2024
Q2 		$68.9K Buy
+1,300
New +$85.2K 0.01% 273

Other funds holding VKTX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Royal Fund Management's VKTX Position: Q2 2026 in Review

Royal Fund Management reduced its Viking Therapeutics (VKTX) stake by 0.16% in Q2 2026, selling an estimated $1.07K and leaving 20,943 shares worth $817K. The position accounts for 0.07% of the portfolio, ranked #201.

Royal Fund Management first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.78M in Q4 2024. 124 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Royal Fund Management held 20,943 shares of Viking Therapeutics worth $817K as of Q2 2026.
  • Royal Fund Management sold 33 Viking Therapeutics shares in Q2 2026, an estimated $1.07K.
  • Viking Therapeutics made up 0.07% of Royal Fund Management's portfolio in Q2 2026, its #201 holding.
  • Royal Fund Management first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Royal Fund Management's Viking Therapeutics position peaked at $1.78M in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.